Kingdon Capital Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Syndax Pharmaceuticals
SNDX
|
+$17.1M |
| 2 |
ECG
Everus Construction Group
ECG
|
+$16.4M |
| 3 |
Western Digital
WDC
|
+$14M |
| 4 |
Maplebear
CART
|
+$13.9M |
| 5 |
Elevance Health
ELV
|
+$13M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$19.1M |
| 2 |
Advanced Micro Devices
AMD
|
+$18M |
| 3 |
FTAI Aviation
FTAI
|
+$15.3M |
| 4 |
APi Group
APG
|
+$14.9M |
| 5 |
Cytokinetics
CYTK
|
+$14.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 24.98% |
| 2 | Industrials | 15.4% |
| 3 | Technology | 11.23% |
| 4 | Consumer Discretionary | 10.98% |
| 5 | Communication Services | 5.65% |
Similar funds
Kingdon Capital Management's Q4 2024 Portfolio in Review
As of Q4 2024, Kingdon Capital Management held 103 positions worth $702M, down 22% from $902M the previous quarter. Its ten largest holdings account for 29% of the portfolio.
Kingdon Capital Management withdrew a net $188M in Q4 2024, closing 33 positions and reducing 18 holdings. Its most notable exit was Abbott, an estimated $19.1M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 25% of assets, down from 26% a quarter earlier, followed by Industrials and Technology.
Against the trend, Kingdon Capital Management opened a new position in Everus Construction Group worth $17.1M.
- Kingdon Capital Management's largest Q4 2024 buy was Everus Construction Group: 260,000 shares worth $17.1M.
- Kingdon Capital Management added most to Syndax Pharmaceuticals in Q4 2024, an estimated $17.1M increase.
- Kingdon Capital Management's biggest Q4 2024 reduction was Insmed, cutting an estimated $12.6M.
- Kingdon Capital Management fully exited Abbott in Q4 2024, selling an estimated $19.1M.
- Kingdon Capital Management's ten largest holdings make up 29% of its $702M portfolio in Q4 2024.
- Kingdon Capital Management opened 24 new positions and closed 33 in Q4 2024.
- Kingdon Capital Management's portfolio value fell 22% quarter-over-quarter to $702M.
Based on Kingdon Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.